Upregulation of PKD1L2 provokes a complex neuromuscular disease in the mouse

Citation for published version:

Digital Object Identifier (DOI):
10.1093/hmg/ddp304

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Human Molecular Genetics

Publisher Rights Statement:
Available under Open Access. Copyright © 2013 Oxford University Press

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Upregulation of PKD1L2 provokes a complex neuromuscular disease in the mouse

Francesca E. Mackenzie1, Rosario Romero1, Debbie Williams1, Thomas Gillingwater2, Helen Hilton1, Jim Dick3, Joanna Riddoch-Contreras3, Frances Wong1,2, Lisa Ireson1, Nicola Powles-Glover1, Genna Riley1, Peter Underhill1, Tertius Hough1, Ruth Arkell1,4, Linda Greensmith3, Richard R. Ribchester2 and Gonzalo Blanco1,*

1MRC Mammalian Genetics Unit, Harwell OX11 0RD, UK, 2Centre for Neuroscience Research, University of Edinburgh, 1 George Square, Edinburgh EH9 1QH, UK, 3Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, Queen Square, London WC1E 6BT, UK and 4Research School of Biological Sciences, The Australian National University, GPO Box 475, Canberra ACT 2601, Australia

Received May 7, 2009; Revised and Accepted July 1, 2009

Following a screen for neuromuscular mouse mutants, we identified oistes, a novel N-ethyl N-nitrosourea-induced mouse mutant with muscle atrophy. Genetic and biochemical evidence shows that upregulation of the novel, uncharacterized transient receptor potential polycystic (TRPP) channel PKD1L2 (polycystic kidney disease gene 1-like 2) underlies this disease. Oistes mice suffer from chronic neuromuscular impairments including neuromuscular junction degeneration, polyneuronal innervation and myopathy. Ectopic expression of PKD1L2 in transgenic mice reproduced the oistes myopathic changes and, indeed, caused severe muscle atrophy in Tg(Pkd1l2)/Tg(Pkd1l2) mice. Moreover, double-heterozygous mice (oistes/+ , Tg(Pkd1l2)/0) suffer from myopathic changes more profound than each heterozygote, indicating positive correlation between PKD1L2 levels and disease severity. We show that, in vivo, PKD1L2 primarily associates with endogenous fatty acid synthase in normal skeletal muscle, and these proteins co-localize to costameric regions of the muscle fibre. In diseased oistes/oistes muscle, both proteins are upregulated, and oistes/oistes mice show signs of abnormal lipid metabolism. This work shows the first role for a TRPP channel in neuromuscular integrity and disease.

INTRODUCTION

Discovering the molecular mechanisms underlying neuromuscular degenerative diseases is pivotal to the development of therapies for such heterogenous disorders. Model organisms have assisted in the identification of novel neuromuscular disease genes and genetic pathways (reviewed in 1–3). We have exploited mouse mutagenesis to identify new neuromuscular mutants. In phenotype-driven screens of mutagenized mice, simple measures of muscle strength such as wheel running or grip strength have failed to consistently identify mutants that show muscular defects at the histological level. In addition, measuring progressive motor neuron loss in mutagenized animals is not a suitable protocol for large-scale screening programmes. In contrast, overt phenotypes such as muscle atrophy, tremors, gait defects and growth retardation have been used to signpost abnormal neuromuscular function in mice (4,5). Using this simple paradigm, we identified oistes in an N-ethyl N-nitrosourea (ENU) screen (6). The aim of this work was to characterize this novel neuromuscular phenotype in the mouse and to provide insights into the underlying molecular mechanism. We present evidence that the product of the genetically linked Pkd1l2 (polycystic kidney disease gene 1-like 2) gene is grossly overexpressed in oistes/oistes mice, and that ectopic expression of PKD1L2 in transgenic mice leads to similar neuromuscular features. To date, no analysis of PKD1L2 protein expression, localization...
or in vivo function has been done. Here, we show that PKD1L2 is the first transient receptor potential polycystic (TRPP) channel to be associated with neuromuscular function and disease. Additionally, we show that abnormal lipid metabolism in PKD1L2-dysregulated mice is a key feature of this disease.

RESULTS

**Ostes** mice show a complex neuromuscular phenotype

We assessed the neuromuscular system in *ostes/ostes* mice at three levels of analysis. Grossly, *ostes/ostes* mice become recognizable by their small size and reduced weight between 3 and 5 weeks of age (Fig. 1A) and remain small and light throughout life (see weights of 12-week-old mice, Fig. 1B). *Ostes/ostes* mice also show a moderate tremor of the hind limbs upon suspension by the tail and have a poor reaching response. Conversely, *ostes/+* mice do not display any overt abnormal phenotype. Sections of 24 *ostes/ostes* tissues including heart did not reveal any pathology except for muscle atrophy (see Supplementary Material, Fig. S1). There is no evidence of macrophage infiltration (Supplementary Material, Fig. S2). Additionally, *ostes/ostes* mice show widespread muscle atrophy, as indicated by the average cross-sectional area of the muscle fibres (Fig. 1D and E) and reflected in the overall muscle group size (see insets in Fig. 1C). Despite the lack of gross phenotype in *ostes/+* mice, similar pathological hallmarks are evident in *ostes/+* hind limb muscle, but the pathology is milder and there is no evidence of muscle atrophy (Fig. 11 and Supplementary Material, Fig. S3), indicating a semi-dominant action of the *ostes* mutation in muscle.

Pyknotic nuclear clumps have been associated with denervation of muscle fibres in amyotrophic lateral sclerosis and bulbospinal muscular atrophy. Therefore, endplates, axons and presynaptic axon terminals in lumbral muscle whole-mounts from 45-day-old *ostes/ostes*, *ostes/+* and wild-type mice were immunostained and examined for signs of denervation. Confocal microscopy revealed many denervated endplates in *ostes/ostes* muscles, characteristically showing a plaque-like morphology, with or without contact to a visible degenerating nerve terminal, or only partially occupied by a small number of nerve terminal boutons (Fig. 1F). Additionally, ~40% of *ostes/ostes* motor endplates were polynerviously innervated by collateral branches of two or three axons. All endplates in wild-type littersmates had only one axon terminal per endplate. We assessed the function of polynerved junctions in *ostes* mice by intracellular recordings of nerve-evoked endplate potentials (EPPs) in extensor digitorum longus (EDL) and soleus muscle from *ostes/ostes* (n = 3) mice. Recordings from *ostes/ostes* muscle in response to graded stimulation of the nerve supply resolved two components of the EPP with distinct thresholds in 20–30% of muscle fibres (n = 15–18 fibres per muscle), indicating functional polynervous innervation (Fig. 1G). These recordings corroborated the morphological evidence of enduring polyneuronal innervation in *ostes/ostes* mice. Fibre type distribution in the soleus muscle region did not show any differences between *ostes/ostes* and wild-type staining. Fibre size asymmetry did not correlate with specific fibre type, and there was no evidence of fibre type grouping (Fig. 11 and Supplementary Material, Fig. S4).

---

**Figure 1.** Neuromuscular phenotypes of *ostes* and *Tg(Pkd1l2)*. (A) Photograph of representative 5-week-old wild-type (+/+), and *ostes/ostes* mice. *Ostes/ostes* mice are small and weigh less than wild-type mice from 3–5 weeks of age. (B) Weight of 12-week-old wild-type (+/+), and *ostes/ostes* mice. Both male and female *ostes/ostes* mice weigh significantly less than wild-type mice at 12 weeks of age (males: P = 5.873E−16, n = 9 *ostes/ostes*, 22 wild-type; males: P = 1.143E−12, n = 11 *ostes/ostes*, 22 wild-type). Data are represented as mean ± SEM. (C) Representative sections of gastrocnemius skeletal muscle from 45-day-old wild-type (+/+), *ostes/ostes*, and *Tg(Pkd1l2)/Tg(Pkd1l2)* mice, stained with H&E. Evidence of degenerative changes are present in *ostes/ostes* muscle, including muscle atrophy, small fibres, striking fibre size asymmetry, pyknotic nuclei and centrally nucleated fibres (arrows). Muscles from 45-day-old *Tg(Pkd1l2)/Tg(Pkd1l2)* mice show similar pathological hallmarks. Scale bar: ×20 magnification, 100 μm, ×40, 50 μm. Inset: H&E-stained levelled cross-sections of whole hind limbs from the same mice show the reduced size and muscle atrophy in *ostes/ostes* and *Tg(Pkd1l2)/Tg(Pkd1l2)* hind limbs. (D) Mean fibre size according to fibre type in soleus muscle from wild-type (+/+), *ostes/ostes* and *Tg(Pkd1l2)/Tg(Pkd1l2)* mice. Mean fibre size in both *ostes/ostes* and *Tg(Pkd1l2)/Tg(Pkd1l2)* skeletal muscle is reduced compared with wild-type. Type-2 fibres show a small but significant reduction in size in *ostes/ostes* and *Tg(Pkd1l2)/Tg(Pkd1l2)*. Fibre size was assessed in *MYH7*-stained sections (slow twitch) of soleus muscle from three 45-day-old mice containing at least 80 fibres each. Data are represented as mean ± SEM. (E) Fibre size distribution in 45-day-old wild-type (+/+), *ostes/ostes* and *Tg(Pkd1l2)/Tg(Pkd1l2)* skeletal muscle. Fibre size was assessed in five H&E-stained sections of gastrocnemius from 45-day-old mice containing at least 80 fibres each. (F) Immunofluorescence photographs of NMJs in wholemount lumbral muscle from wild-type (+/+), *ostes/ostes* mice. Acetylcholine receptors are labelled in red, and presynaptic boutons and axons in green. Wild-type (+/+), endplates are mononeuronally innervated, with one axon leading to each endplate. *Ostes* endplates show both normal mononeuronal innervation (µ), alongside abnormal polynervous innervation (ν) where two or more axon terminals innervate one endplate, in both 45-day-old and 9-month-old mice. In addition, some *ostes* endplates are denervated (δ), characterized by a plaque-like morphology of acetylcholine receptor staining and only partial or absent occupation by axon terminals. Scale bar, 20 μm. (G) Example of an intracellular recording of nerve-evoked EPPs from an *ostes/ostes* EDL muscle, showing functional polynervous innervation. (H) Immunofluorescence photographs of NMs in wholemount hind limb muscle from 26-day-old *Tg(Pkd1l2)/Tg(Pkd1l2)* mice. Examples of an abnormal polynervous innervation (µ) and a plaque-like partially denervated endplate (δ) are shown. (I) Fibre type analysis of levelled cross-sections of 45-day-old +/+ , *ostes/ostes* and *Tg(Pkd1l2)/Tg(Pkd1l2)* hind limb skeletal muscle. There is no evidence of fibre type grouping, and fibre size asymmetry does not correlate with specific fibre type in either *ostes/ostes* or *Tg(Pkd1l2)/Tg(Pkd1l2)* muscle. (J) Representative sections of gastrocnemius skeletal muscle from aged (>6 months) *ostes/+*, *Tg(Pkd1l2)/0*, and *ostes/+*, *Tg(Pkd1l2)/0* mice, stained with H&E. *Ostes/+* skeletal muscle shows similar but much milder pathological hallmarks than *ostes/ostes* muscle, and no evidence of overall muscle atrophy. Skeletal muscle from hemizygous *Tg(Pkd1l2)/0* mice does not show any obvious myopathic changes or atrophy. However, skeletal muscle from aged *ostes/+*, *Tg(Pkd1l2)/0* mice shows marked fibre size asymmetry, very small fibres and centrally nucleated regenerating fibres. Scale bar: ×20, 100 μm, ×40, 50 μm. Inset: H&E-stained cross-sections of whole hind limbs from the same mice show no significant differences in size.
To assess whether this polyinnervation was due to a delay in developmental synapse elimination at the neuromuscular junction (NMJ), we examined motor endplates in 9-month-old ostes/ostes mice (Fig. 1F). Polyinnervated endplates were also observed in these mice, suggesting that this phenotype was persistent and not due to prolongation of the period over which synapse elimination would normally occur (1–2 weeks postnatal). Ostes/+ mice also showed evidence of polyinnervation, but at lesser incidence than ostes/ostes mice, and polyinnervation was not unequivocally found to be functional (n = 2 mice, data not shown). In both young and old ostes/ostes and ostes/+ mice, normal mononeuronal innervation of endplates was also observed (Fig. 1F). Therefore, three distinctive types of endplates were characteristically observed in lumbrical muscles from ostes/ostes mice: monoinnervated (~50%, n = 3), denervated (~10%, n = 3) and polyinnervated (~40%, n = 3).

The specific effects of the morphological changes in ostes/ostes muscle on muscle function were also established. We found that the hind limb muscles of ostes/ostes mice were weaker than the corresponding muscles in age-matched wild-type controls. Whereas tibialis anterior (TA) muscles in wild-type mice produced a maximum tetanic force of 137g (± 5.3 SEM, n = 6), this was reduced to only 32g (± 2.1 SEM, n = 10) in ostes/ostes mice (Fig. 2A). Similarly, the maximum force in EDL muscles of wild-type mice was 25g (± 3.1 SEM, n = 8) compared with only 13g (± 0.8 SEM, n = 7) in ostes/ostes mice (Fig. 2A). The contractile characteristics of these muscles in ostes/ostes mice were also assessed. Although the time to peak force and the time taken to reach half relaxation force were the same in TA and EDL muscles of ostes/ostes and wild-type mice (Fig. 2B), there was a significant change in the fatigue characteristics of EDL muscles in ostes/ostes mice (Fig. 2C). EDL is normally a fast muscle that fatigues rapidly when repeatedly stimulated (Fig. 2C). However, EDL in ostes/ostes mice has a higher fatigue index than that of wild-type (Fig. 2C), indicating that it has become more fatigue resistant than normal.

Despite the presence of some denervated NMJs, the loss of muscle force and change in fatigue characteristics observed in hind limb muscles of ostes/ostes mice were not due to a loss of motor units. Physiological assessment of motor unit survival showed that EDL muscles in wild-type and ostes/ostes mice were innervated by an average of 38.8 (± 1.17 SEM, n = 6)
and 36.7 (± 0.88 SEM, n = 6) motor neurons, respectively (Fig. 3A). This finding, indicating that there was no loss of motor axons in ostes/ostes mice, was supported by morphological assessment of motor neuron survival (Fig. 3B). We found no difference in the number of motor neurons present in the lumbar spinal cord of ostes/ostes mice and wild-type littermates (Fig. 3B). This was supported by the lack of muscle paralysis in either ostes/+ or ostes/ostes mice at any age. Additionally, cross-sections of sciatic nerve showed no evidence of demyelination in ostes/ostes mice (n = 3) (Fig. 3C).

The ostes mutation maps to a 0.78 Mb region on distal chromosome 8

The ostes mutant was identified in a complex recessive mouse mutagenesis screen that involved ENU treatment of a hybrid (C3H/HeH × 101/H) strain (6). To facilitate genetic and functional analysis, the ostes line was crossed to wild-type BALB/c mice for 20 generations to generate a congenic ostes line. Genetic mapping on ostes/ostes progeny from these crosses established linkage to distal chromosome 8 between D8Mit213 and D8Mit13. Two further outcrosses, to the C57BL/6J and FVB inbred strains, also independently confirmed significant linkage to the same region on chromosome 8 (data not shown). Since the FVB strain showed the highest rate of polymorphism with the initial mutagenized background, this strain was selected for high-resolution mapping. We generated and genotyped approximately 500 intercross progeny including both affected (ostes/ostes) and non-affected (+/+ and ostes/+ ) offspring to utilize all recombination events. This analysis refined the non-recombinant region to 772 kb, between D8Mit89 and the in-house marker FM3 (see Materials and Methods). Pkd1l2, Gcsh, Bcmo1, Dynlrb2 and five additional predicted genes lie within this region, comprising 94 coding exons in total (Ensembl v49, May 2008; Supplementary Material, Table S1). All exons and splice acceptor/donor sites were amplified by PCR from genomic ostes/ostes DNA and screened for mutation by sequencing, but intriguingly, no mutation was revealed. To confirm this finding, we used a commercial next-generation sequencing approach (NGS) to sequence all exons in the interval. As no mutation in coding sequence was identified, this analysis confirmed our previous results (see Materials and Methods). To screen for cDNA variants, cDNA of all candidate genes except Pkd1l2 was successfully amplified and sequenced from primary cDNA libraries from wild-type and ostes/ostes tissues. This analysis revealed no ostes-specific splicing variants of these genes. Therefore, this raised the possibility that the ostes mutation could lie in a regulatory element and that misregulation of one of these genes, rather...
than a coding mutation, could underlie the \textit{ostes} phenotype. Intriguingly, 30 sets of primers in a large number of combinations failed to amplify overlapping segments of the large \textit{Pkd1l2} cDNA from several tissues including the liver, kidney and muscle; therefore, a complete sequence scan for this particular cDNA was not achieved.

To evaluate expression, we performed microarray analysis on adult \textit{ostes/ostes} and wild-type hind limb skeletal muscle using the RNG-MRC Mouse 25k array (MRC Harwell) which contained all of the nine genes from the non-recombinant region. No significant differences in the expression of these genes between \textit{ostes/ostes} and wild-type samples were found (Supplementary Material, Fig. S5A; data deposited at ArrayExpress, accession number E-MEXP-1873). \textit{Pkd1l2} was the only gene in this region for which analysis of splicing variants or differences in expression could not be established despite its reported expression in skeletal muscle (7). This was not due to technical problems, because detection of \textit{Pkd1l2} to levels amenable for analysis failed in direct cDNA amplifications, Q-PCR (see what follows) and microarray experiments, whereas cDNAs from other genes in the non-recombinant region were efficiently detected using the same techniques and templates. However, we considered \textit{Pkd1l2} to be a good candidate on the basis of

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure3}
\caption{Motor neuron survival in \textit{ostes}. (A) Assessment of motor unit number in \textit{ostes/ostes} EDL. Examples of stepwise increments in twitch force from wild-type (+/+ and \textit{ostes/ostes} EDL in response to gradual intensity increases of stimulation of the motor nerve to the EDL. Motor unit number in \textit{ostes/ostes} EDL is not significantly different to wild-type EDL (\(n = 6\) per genotype). Data shown as mean motor unit number ± SEM. (B) Motor neuron survival in \textit{ostes/ostes} mice. Shown are representative 20 \textmu m-thick transverse sections of spinal cord from wild-type and \textit{ostes/ostes} mice. Motor neurons are stained with gallocyanin (blue). Data shown as mean motor neuron counts ± SEM. The number of gallocyanin-stained motor neurons present in the sciatic motor pool of the ventral horn of each spinal cord was determined by counting every third serial section (\(n = 60\) sections per mouse; \(n = 6\) per genotype). (C) Representative cross-section of proximal regions of sciatic nerve from 6-week-old wild-type (+/+ and \textit{ostes/ostes} mice (\(n = 3\) each) fixed with osmium tetroxide and stained with methylene blue. No demyelination of \textit{ostes/ostes} motor neurons as evidenced by reduced myelin-to-lumen staining or by 'onion-bulb' morphology is seen. Note that \textit{ostes/ostes} motor neurons are markedly smaller than wild-type, reflecting the overall small size of \textit{ostes/ostes} mice. Scale bar: 25 \textmu m.}
\end{figure}
the association of the homologous PKD1 gene with disease and the fact that all genes in the non-recombinant region except Pkd1l2 had been effectively ruled out. Thus, for all these other genes, no coding or splicing mutations and no significant expression differences between the mutant and control were found. Therefore, we decided to assess expression of Pkd1l2 in ostes/ostes mice at the protein level.

**PKD1L2 protein is upregulated in ostes mice**

We assessed Pkd1l2 as a candidate gene for ostes by generating PKD1L2-specific antibodies and examining PKD1L2 protein in ostes/ostes muscle. Two rabbit polyclonal antibodies, APKD1L2_1 and APKD1L2_2, were generated and thoroughly characterized (Fig. 4). Western blot analysis of soluble skeletal muscle extracts from wild-type mice showed that both antibodies recognized a band migrating at ~268 kDa (Fig. 4B), consistent with the PKD1L2 expected size (272 kDa). Western blot analysis of multiple tissues showed that this band was the largest protein recognized in several tissues (Supplementary Material, Fig. S6A), suggesting that this protein is likely to be full-length PKD1L2. We used immunoprecipitation to confirm the specificity of these antibodies. Antibody APKD1L2_1 specifically and efficiently immunoprecipitated a protein migrating at ~268 kDa band from protein complexes immunoprecipitated using APKD1L2_1 antibody in skeletal muscle soluble fraction, from both wild-type and ostes/ostes mice. Western blot analysis using PKD1L2 antibody specifically recognizes a ~268 kDa band from protein complexes immunoprecipitated using AFASN antibody in skeletal muscle soluble fraction, from both wild-type and ostes/ostes mice. PKD1L2 and FASN co-immunoprecipitation was also observed in membrane fractions (bottom panels). IP, immunoprecipitation; WB, western blot; Lys, lysate; IP+, immunoprecipitated sample; IP−, negative control.
soluble and membrane fractions (Fig. 5). These results suggested that the upregulation of PKD1L2 underlies the ostes phenotype.

In search of a putative regulatory mutation within the vicinity of the Pkd1l2 gene that would explain the upregulation of this gene in mutant mice, we used NGS to sequence unique non-coding sequences in a 250 kb genomic segment encompassing Pkd1l2 and flanking genes Bcmo1 and Gcsh, that is, all genomic DNA except repetitive elements in that interval. This analysis produced 149 kb of sequence from ostes/ostes DNA, but no change was revealed, suggesting that a regulatory mutation could exist in a non-conserved regulatory element somewhere else within the non-recombinant interval.

Transgenic overexpression of PKD1L2 causes ostes-like myopathic and innervation changes

We tested the hypothesis that the overexpression of PKD1L2 found in ostes/ostes mice causes neuromuscular dysfunction in these mice by generating a transgenic mouse overexpressing PKD1L2. Since a full-length Pkd1l2 cDNA could not be amplified (discussed earlier), we opted to use a bacterial artificial chromosome (BAC) to generate a transgenic line. A BAC (RP23-269J16) was selected which contained the full-length genomic sequence of Pkd1l2 and the small flanking genes Bcmo1 and Gcsh. These flanking sequences were required to include the promoter and other possible regulatory elements in the vicinity of the Pkd1l2 gene. Following microinjection of the BAC into fertilized oocytes, a transgenic founder was identified (Tg(Pkd1l2)#1). Subsequent crosses showed that the BAC was transmitted to 57.5% (57 of 99) of offspring from this mouse, thus indicating a single integration site. We examined hemizygous Tg(Pkd1l2)/0 mice for evidence of neuromuscular dysfunction. Tg(Pkd1l2)/0 mice were indistinguishable from wild-type littermates and did not show any overt phenotype, and histological analysis again showing a lack of both fibre-specific hypertrophy and clustering (Fig. 1I and Supplementary Material, Fig. S4). However, both ostes and Tg(Pkd1l2) homozygotes showed a small but statistically significant reduction of type-2 fibre size in soleus muscle (Fig. 1D). Additionally, polyinnervated and denervated endplates were also evident in homozygous Tg(Pkd1l2)/Tg(Pkd1l2) mice (n = 4, representative examples shown in Fig. 1H).

Given the similarities between the ostes and Tg(Pkd1l2) myopathies, these results theoretically reduced the genetic cause of the ostes disease to the upregulation of any of the three genes in the BAC: Bcmo1, Pkd1l2 or Gcsh. We had already established that PKD1L2 protein was elevated in ostes mice. To unequivocally establish how expression levels of these three candidate genes correlated with the ostes neuromuscular disease, further expression analysis was carried out. Real-time quantitative PCR was performed using skeletal muscle from 10 ostes/ostes mice and 10 age- and sex-matched wild-type controls. The results were consistent with the microarray results described earlier: expression of Bcmo1 or Gcsh was not significantly different in ostes/ostes mice (Supplementary Material, Fig. S5B), whereas Pkd1l2 was not detected at sufficient levels for a reliable analysis. Therefore, Bcmo1 and Gcsh have no coding or regulatory mutations in ostes/ostes mice. Western blot analysis of skeletal muscle from Tg(Pkd1l2)/Tg(Pkd1l2) mice showed that full-length PKD1L2 was indeed overexpressed in this line (Fig. 5). Further proof that the myopathies described in ostes and Tg(Pkd1l2) homozygous mice share a common pathogenic mechanism could be obtained from making double heterozygotes. Thus, if ectopic expression of PKD1L2 as a result of an ENU mutation or expression from a BAC clone was respectively underlying myopathic changes in ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) mice, we could expect double-heterozygous mice (ostes/+; Tg(Pkd1l2)/0) to show a more severe pathology than the mild changes observed in ostes/+ mice. In young mice, approximately 45 days old, the presence of the BAC clearly exacerbated the mild myopathic changes of ostes heterozygotes without adding any new distinctive feature.
PKD1L2 interacts with fatty acid synthase in vivo

Our data showed that overexpression of PKD1L2 was associated with neumuscular dysfunction in two mouse mutants. However, neither PKD1L2 nor other TRPP channels have previously been shown to have roles in muscle. To explore a molecular role for PKD1L2 in muscle, we examined PKD1L2 protein complexes by immunoprecipitation from adult mouse skeletal muscle lysates. Immunocomplexes precipitated with antibody APKD1L2_1 were analysed by SDS–PAGE and mass spectrometry to identify PKD1L2-interacting proteins. Upon gel staining, a very prominent band was observed migrating at ~268 kDa, which was absent in the negative control lane (Fig. 4C). A peptide mass fingerprint was generated from this band by mass spectrometry. Database search using ProFound identified PKD1L2, as expected, but additionally the enzyme fatty acid synthase (FASN) was identified as the top scorer. FASN was also identified from bands of smaller molecular weight, probably reflecting partial degradation (Fig. 4C). The identity of this protein was confirmed by western blot with a monoclonal antibody against FASN (mAFASN) following immunoprecipitation with APKD1L2_1 antibody, from both wild-type and ostes/ostes skeletal muscle soluble fractions (Fig. 4D). To further confirm the association between PKD1L2 and FASN, we carried out immunoprecipitation using mAFASN on wild-type and ostes/ostes skeletal muscle soluble fractions. FASN was efficiently immunoprecipitated, and subsequent western blot analysis confirmed that PKD1L2 was present in the immunoprecipitated complex. The same results were obtained using wild-type skeletal muscle membrane fraction (Fig. 4D). Since the molecular weight of FASN is equivalent to that of PKD1L2 (272 kDa), and the two proteins co-migrate, this analysis did not exclude the possibility that the APKD1L2_1 antibody might be cross-reacting with FASN protein. To test for such cross-reactivity, we examined PKD1L2 and FASN protein expression in different mouse tissues. This analysis demonstrated that whereas FASN was strongly expressed in every tissue examined, expression of PKD1L2 was more restricted, thus indicating that the APKD1L2_1 antibody does not recognize FASN (Supplementary Material, Fig. S6A). Analysis of the same samples using non-denaturing conditions produced a different pattern for both antibodies on western blots (data not shown), suggesting that PKD1L2_1 antibodies did not cross-react against the FASN native form either. Moreover, affinity-purified antibody APKD1L2_2, raised against a different PKD1L2 epitope, also immunoprecipitated FASN (Supplementary Material, Fig. S6B), and the reciprocal immunoprecipitation using mAFASN antibody also produced a ~268 kDa protein recognized by antibody APKD1L2_2, confirming the co-immunoprecipitation of FASN and PKD1L2 (Supplementary Material, Fig. S6B).

Despite PKD1L2 being a predicted transmembrane protein and FASN a soluble cytoplasmic enzyme, their association as revealed by immunoprecipitation of endogenous proteins suggested that these proteins must have overlapping subcellular localizations. To assess this, immunostainings on cross- and longitudinal sections of fresh-frozen skeletal muscle samples were performed with APKD1L2_1 and a goat polyclonal antibody against FASN (gAFASN). PKD1L2 and FASN were found localized to the membrane on cross-sections (Fig. 6A). On longitudinal sections, both antibodies produced overlapping localizations at striations overlying the Z-discs on the surface of the fibre (Fig. 6A, middle panel) but not at the centre (Fig. 6A, bottom panel). A similar result was obtained with mAFASN antibody (Supplementary Material, Fig. S7), suggesting a costameric localization of both proteins. Costameric distribution was supported by co-localization of PKD1L2 with the costameric transmembrane protein β-dystroglycan (8) on serial views of longitudinal sections (Fig. 6C). An identical pattern was observed with antibody APKD1L2_2, and for both PKD1L2 antibodies, the fluorescent signal was effectively blocked upon pre-incubation with their respective antigenic peptides (data not shown). On the other hand, expression of PKD1L2 was also detected at slightly higher levels at the postsynaptic membrane of the NMJs (Fig. 7A and B).

FASN is overexpressed in ostes mice

We speculated that the overexpression of PKD1L2 in ostes/ostes skeletal muscle could affect the expression or activity of FASN in this tissue. Surprisingly, we found that FASN was overexpressed in ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) skeletal muscle by western blot analysis, mirroring the overexpression of PKD1L2 (n = 12, representative samples shown in Fig. 5). Overexpression of FASN was observed in both soluble and membrane fractions (Fig. 5) and was also confirmed to occur at the transcriptional level (Supplementary Material, Fig. S8A). The growth defect exhibited by the ostes mouse is counterintuitive to an overexpression of FASN, as the latter is generally found in conditions of metabolic overload such as obesity (reviewed in 9). We therefore hypothesized that PKD1L2 acts as a negative regulator of FASN and that the upregulation of PKD1L2 in the ENU and transgenic lines results in decreased FASN activity. In this hypothesis, the increased expression of FASN in skeletal muscle of ostes mice would result from a positive feedback regulatory mechanism. Relative activity of FASN to total amount of

(Supplementary Material, Fig. S3). This result suggests that increasing the copy number of the Pkd1l2 gene results in worsening of the pathology caused by the ENU mutation. Moreover, ostes/+, Tg(Pkd1l2)/0 mice (n = 3) showed a late-onset muscular atrophy and weakness of the hind limbs between 6 and 10 months old, with foot-curling, unstable gait and similar myopathic changes to those observed in ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) muscles (Fig. 1J). These features were not found in aged ostes/+ (n = 6) or Tg(Pkd1l2)/0 mice (n = 3) (Fig. 1J). These results indicated that ostes and Tg(Pkd1l2) interact genetically and strongly supported the hypothesis that the upregulation of PKD1L2 causes neumuscular disease. These results did not strictly exclude the possibility that a new mutation caused by the insertion of the BAC and not the BAC itself was responsible for the phenotype observed in the transgenic line. However, the specificity of the pathological changes in the ENU-induced and BAC-induced mutant lines and the genetic interaction between the underlying genetic loci made that possibility unlikely.
FASN protein was measured in soluble fractions of *ostes*/*ostes* and wild-type muscle by spectrophotometric analysis of NADPH > NADP+ oxidation. Although there is a clear trend showing reduced relative activity in *ostes*/*ostes* mice, FASN activity varied widely in individual samples of the same genotype, making the difference between *ostes*/*ostes* and control statistically not significant (*P* = 0.236) (Supplementary Material, Fig. S8B). Therefore, we looked for other biochemical markers of lipid metabolism to determine whether fatty acid biosynthesis was abnormal in *ostes*/*ostes* mice. We assessed the blood plasma lipid profile of *ostes*/*ostes* mice (Fig. 8A). Both triglyceride (TG) and free fatty acid (FFA) levels were significantly and markedly decreased in plasma from both male and female *ostes*/*ostes* mice, compared with

![Figure 6. Co-localization of PKD1L2 and FASN in skeletal muscle. (A) Confocal microscopic analysis of fresh-frozen skeletal muscle sections from wild-type mice immunostained with APKD1L2_2 and gAFASN antibodies. Top panel, a cross-section of muscle showing PKD1L2 and FASN co-localization at the membrane. Middle panel: a view of the surface of longitudinally sectioned fibres showing PKD1L2 and FASN with overlapping localizations to striations. Bottom panel: a deeper level of the same fibres showing PKD1L2 and FASN with overlapping localizations at the membrane. (B) For comparison, a view of the mid-level of a longitudinal fibre stained with dystrophin and α-actinin using the same conditions. Note that, in contrast to the bottom panel shown in (A), the Z-discs are stained here. (C) Top panel: superficial ("Top") and middle views of longitudinal fibres showing PKD1L2 co-localization with the costameric protein β-dystroglycan. Bottom panel: a close-up view of top and middle levels of a single fibre. Scale bar: 25 μm.](http://hmg.oxfordjournals.org/ "Downloaded from http://hmg.oxfordjournals.org/"")
wild-types (Fig. 8A). Furthermore, total body fat content of ostes/ostes mice was analysed by dual-energy X-ray absorptiometry (DEXA) analysis (Fig. 8B). The total fat percentage of body mass was significantly decreased in ostes/ostes mice from a mean wild-type percentage of $\sim20$ to $\sim17\%$ in female ostes/ostes mice and from $\sim17$ to $\sim14\%$ in male ostes/ostes mice (Fig. 8B). These results indicated a reduction of lipogenesis in ostes mice.

**DISCUSSION**

In this work, we have characterized the neuromuscular phenotype of ostes mice and explored the underlying molecular mechanism. Indeed, the genetic mechanism leading to the upregulation of the linked Pkd1l2 gene in ostes mice remains elusive despite meticulous sequencing efforts. However, as indicated by the total protein levels, Pkd1l2 is
the only gene in the non-recombinant region that is upregulated in ostes/ostes mice, and there are identical pathological findings in ostes/ostes and Tg(Pkd1l2)/Tg(Pkd1l2) mice. Common histological hallmarks include muscle fibre asymmetry, scattered regenerating fibres, a lack of fibre type grouping, and increased levels of both TG and FFA (TG: female: P = 3.107E − 05; male: P = 0.0001; FFA: female: P = 0.0005; male: P = 2.221E − 06). Data represented are mean blood plasma levels ± SEM. (B) Total percentage body fat in ostes/ostes mice. Total body fat was analysed by DEXA analysis in ostes/ostes (n = 9 female, 11 male) and wild-type (n = 12 female, 12 male) mice. Total percentage body fat was significantly decreased in both female and male ostes/ostes mice, compared with wild-type (female: P = 1.92E − 03, male: P = 5.02E − 06). Data represented are mean percentage body fat ± SEM.

Figure 8. Lipid metabolism in ostes mice. (A) Lipid profiling in ostes/ostes mice. Blood lipids were analysed from fasted ostes/ostes (n = 9 female, 11 male) and wild-type (n = 12 female, 12 male) mice for triglyceride (TG) and free fatty acid (FFA). Both male and female ostes/ostes mice showed significantly decreased levels of both TG and FFA (TG: female: P = 3.107E − 05; male: P = 0.0001; FFA: female: P = 0.0005; male: P = 2.221E − 06). Data represented are mean blood plasma levels ± SEM. (B) Total percentage body fat in ostes/ostes mice. Total body fat was analysed by DEXA analysis in ostes/ostes (n = 9 female, 11 male) and wild-type (n = 22 female, 22 male) mice. Total percentage body fat was significantly decreased in both female and male ostes/ostes mice, compared with wild-type (female: P = 1.92E − 03, male: P = 5.02E − 06). Data represented are mean percentage body fat ± SEM.

Given that muscle has a particularly high metabolic need for fatty acids driven by its high-energy demand, a reduction in FASN activity would predictably compromise muscle function. In fact, blood measurements of TGs and FFAs as well as total fat deposition would suggest that lipid metabolism is indeed compromised in the ostes homozygote. Given that muscle has a particularly high metabolic need for fatty acids driven by its high-energy demand, a reduction in FASN activity would predictably compromise muscle function. Mice homozygous for a null allele of FASN show embryonic lethality (22), but skeletal muscle was not examined in surviving Fasn heterozygous mice. A direct involvement of FASN activity in muscle disease or indeed the pathogenic mechanism of ostes cannot be tested at the
present time, as a Fasn skeletal-muscle conditional knockout mouse has not been reported. However, a rare case of de novo fatty acid synthesis deficiency resulting in persistent myopathy and poor growth has been reported in humans. This defect was due to the deficiency of the acetyl-CoA carboxylase enzyme, which catalyses the formation of the FASN substrate malonyl-CoA (23), indicating that insufficient fatty acid synthesis can cause pathological changes in skeletal muscle. Moreover, the microarray data generated in this work identified lipid metabolism as the major biological pathway altered in ostes/ostes skeletal muscle: eight out of the top nine genes upregulated in ostes/ostes muscle have functions in lipid metabolism (Supplementary Material, Table S2; see also deposited data ArrayExpress, accession number E-MEXP-1873). Therefore, lipogenesis is altered at skeletal muscle and systemic levels in ostes/ostes mice. The precise reasons for the tissue specificity of this disease remain to be established. Concomitant upregulation of FASN and PKD1L2 was also detected in the kidney, but here the increase in FASN is smaller than that observed in muscle; overexpression of both PKD1L2 and FASN was not detected in other tissues from ostes/ostes mice, including the brain, spinal cord and liver (Supplementary Material, Fig. S10A). In conclusion, our data suggest that PKD1L2-induced dysregulation of lipid metabolism is a cause of complex neuromuscular defects in mice. On that basis, we propose that PKD1L2 and defective fatty acid synthesis should be assessed, respectively, as a genetic risk factor and as a precipitating cause of neuromuscular disorders in humans.

MATERIALS AND METHODS

Additional methods are detailed in Supplementary Material.

Antibodies

Polyclonal antibodies to mouse PKD1L2 were generated in rabbit using two PKD1L2 peptides (APKD1L2_1: LVASTKVRPDEDORRQEATRA; APKD1L2_2: GNSKLV GSAHIRQVRVRE) and independently affinity-purified (NeoMPS Inc., San Diego, CA, USA).

Genetic mapping

The in-house-generated marker used was a microsatellite marker FM3 (forward primer: 5'-TCTGGGTGGATGGA-CATT-3'; reverse primer: 5'-CCCAGATGATGGAAGGA GAA-3'). The ostes locus was genotyped on an FVB genetic background using D8Mit89 and D8Mit120 (MGI), and rs37591388 (NCBI).

BAC transgenesis

A BAC (identifier RP23-269J16) containing full-length genomic sequence of Pkd1l2 was obtained from BACPAC Resource Center, Children’s Hospital Oakland Research Institute (CHORI), Oakland, CA 94609, USA. DNA was prepared from culture using the QIAGEN Large-Construct Kit, diluted to 1 ng/µl and microinjected into fertilized FVB oocytes. Resulting mice were screened for BAC integration by PCR with primers designed against the vector: forward 5'-ataaat ggatgccctgctga-3'; reverse 5'-ttcaacccagcagctct-3'. One positive founder for the BAC was identified and bred to the FVB strain to generate a colony. The line was submitted to the Mouse Genomic Nomenclature Committee (The Jackson Laboratory) and designated the identifier Tg(Pkd1l2)1Blac (accession number MGI:3811813). For brevity, we refer to this line in this publication by the shortened identifier Tg(Pkd1l2).

FASN activity assay and HeLa cell culture

FASN-specific activity in soluble fraction of skeletal muscle from 3-month-old female wild-type (n = 4) and ostes/ostes (n = 4) mice was measured as described in Nepokroeff et al. (24), except that mice were fed ad libitum before sacrificing. Untreated, and serum-deprived and insulin-treated, HeLa cells were used as positive control. HeLa cell culture, treatment and protein isolation were performed as described in Alberts et al. (25). FASN protein amounts were quantified by densitometric analysis using QuantityOne software (Bio-Rad) from western blot of equally loaded cytosolic fractions and were normalized to GAPDH. FASN relative activity was calculated using the following formula: FASN activity = FASN-specific activity (units/mg/min)/FASN total protein (arbitrary units). Statistical testing was performed using a two-tailed Student’s t-test.

SUPPLEMENTARY MATERIAL

Supplementary Material is available at HMG online.

ACKNOWLEDGEMENTS

We thank Richard Gale, Rama Kurapati, James Green and MGU core facilities for technical assistance.

Conflict of Interest statement. None declared.

FUNDING

Funding for this work and to pay the Open Access publication charges for this article was provided by the UK Medical Research Council.

REFERENCES


